View Author
patient factor polymorphism study restenosi genotype leiden level thrombosis haplotype inhibitor plasminogen activator inhibitor 1000521777 | ip association subject fibrinolysi thrombin-activatable fibrinolysis inhibitor splanchnic vein thrombosis allele center plasma thromb department factor v leiden 2012-08-03 | id effect analysis diabetes splanchnic 2012-08-08 | id university portal vein thrombosis variant table 147thr plasminogen activator stent smoker blood tafi gene disease control leiden university 4 g variant –438 carrier ala 147thr snp cardiology downloaded thrombin-activatable venou right 130.115.200.143 permission portal variation haplotype analysis tafi snps procoagulant polymorphisms risk factors 325ile 325 ile allele haemost –438 ga genotype antigen –438 g /a result –438 gg genotype group budd-chiari syndrome syndrome follow-up heart tafi concentration percutaneou netherland tafi levels system stent placement
2 Most Recent Publications
|
The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions
(Article)
Pons, D. Monraats, P.S. Winter, R.J. de Tio, R.A. Frants, R.R. Laarse, A. van der Wall, E.E. van der Jukema, J.W. Maat, M.P.M. de Pires, N.M.M. Quax, P.H.A. Vlijmen, B.J.M. van Rosendaal, F.R. Zwinderman, A.H. Doevendans, P.A. Waltenberger, J. |
2007-12-01
|
|
Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis
(Article)
Bruijne, E.L.E. de Murad, S.D. Maat, M.P.M. de Tanck, M.W.T. Haagsma, E.B. Hoek, B. van Rosendaal, F.R. Janssen, H.L.A. Leebeek, F.W.G. |
2007-02-01
|
